Arrowhead Pharmaceuticals Company Insiders
| ARWR Stock | USD 22.33 0.28 1.24% |
Slightly above 89 percent of Arrowhead Pharmaceuticals' insiders are activelly selling. The analysis of the overall insider sentiment regarding Arrowhead Pharmaceuticals suggests that quite a large number of insiders are panicking. Arrowhead Pharmaceuticals employs about 525 people. The company is managed by 28 executives with a total tenure of roughly 187 years, averaging almost 6.0 years of service per executive, having 18.75 employees per reported executive.
| Christopher Anzalone CEO CEO and President Director, CEO of Calando, CEO of Tego, CEO of Nantope, CEO of Leonardo and CEO of Ablaris Therapeutics |
| Douglas Given Chairman Chairman of the Board |
Arrowhead Pharmaceuticals' Insider Buying Vs Selling
11
Selling | Buying |
Latest Trades
| 2024-03-20 | Hongbo Lu | Acquired 1000 @ 27.5 | View | ||
| 2024-03-18 | Hongbo Lu | Acquired 1000 @ 27.49 | View | ||
| 2024-03-06 | Kenneth Allen Myszkowski | Disposed 40000 @ 35.19 | View | ||
| 2024-01-31 | Christopher Richard Anzalone | Disposed 57499 @ 32.35 | View | ||
| 2024-01-12 | James C Hamilton | Disposed 7940 @ 36.89 | View | ||
| 2024-01-11 | Douglas B Given | Disposed 2911 @ 38.06 | View | ||
| 2024-01-05 | Patrick O'brien | Disposed 22841 @ 35.27 | View | ||
| 2024-01-03 | Patrick O'brien | Disposed 8749 @ 32.28 | View | ||
| 2024-01-02 | Christopher Richard Anzalone | Disposed 9952 @ 31.01 | View | ||
| 2023-12-20 | Christopher Richard Anzalone | Disposed 12000 @ 28.54 | View | ||
| 2023-11-20 | Martin Javier San | Disposed 19700 @ 28.8 | View | ||
| 2023-10-25 | Christopher Richard Anzalone | Disposed 24338 @ 24.21 | View | ||
| 2023-09-28 | Victoria Vakiener | Disposed 1550 @ 26.33 | View | ||
| 2023-09-18 | Christopher Richard Anzalone | Disposed 57755 @ 28.12 | View | ||
| 2023-07-03 | Tracie Oliver | Disposed 8925 @ 35.31 | View | ||
| 2023-06-30 | James C Hamilton | Disposed 3000 @ 35.53 | View | ||
| 2023-06-27 | Kenneth Allen Myszkowski | Disposed 15000 @ 36.2 | View |
Monitoring Arrowhead Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Arrowhead |
Arrowhead Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Arrowhead Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Arrowhead will maintain a workforce of slightly above 530 employees by May 2024.Arrowhead Pharmaceuticals' latest congressional trading
Congressional trading in companies like Arrowhead Pharmaceuticals, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Arrowhead Pharmaceuticals by those in governmental positions are based on the same information available to the general public.
| 2023-01-31 | Representative Daniel Goldman | Disposed Under $15K | Verify |
Arrowhead Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.2466) % which means that it has lost $0.2466 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0624) %, meaning that it created substantial loss on money invested by shareholders. Arrowhead Pharmaceuticals' management efficiency ratios could be used to measure how well Arrowhead Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/19/2024, Return On Tangible Assets is likely to drop to -0.26. In addition to that, Return On Capital Employed is likely to drop to -0.32. At this time, Arrowhead Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 04/19/2024, Non Current Assets Total is likely to grow to about 790.5 M, while Other Assets are likely to drop slightly above 229.4 K.As of 04/19/2024, Common Stock Shares Outstanding is likely to grow to about 128.9 M, though Net Loss is likely to grow to (175.5 M).
Arrowhead Pharmaceuticals Workforce Comparison
Arrowhead Pharmaceuticals is rated below average in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 10,774. Arrowhead Pharmaceuticals holds roughly 525 in number of employees claiming about 5% of equities under Health Care industry.
Arrowhead Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of (1.63) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (38.45) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $38.45.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.57 | 0.85 |
|
|
Arrowhead Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arrowhead Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arrowhead Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Arrowhead Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 0.2308 | 9 | 39 | 445,499 | 283,716 |
| 2023-12-01 | 1.5 | 6 | 4 | 89,922 | 56,038 |
| 2023-09-01 | 0.5 | 2 | 4 | 115,310 | 68,230 |
| 2023-06-01 | 0.25 | 2 | 8 | 104,928 | 234,356 |
| 2023-03-01 | 0.7917 | 19 | 24 | 332,720 | 73,830 |
| 2022-12-01 | 0.75 | 3 | 4 | 284,400 | 82,125 |
| 2022-09-01 | 0.2 | 1 | 5 | 2,501 | 596,823 |
| 2022-03-01 | 0.325 | 13 | 40 | 1,177,994 | 424,757 |
| 2021-12-01 | 0.2 | 3 | 15 | 40,461 | 188,361 |
| 2021-03-01 | 0.3929 | 11 | 28 | 1,114,500 | 328,913 |
| 2020-12-01 | 0.25 | 10 | 40 | 213,847 | 561,904 |
| 2020-09-01 | 0.3333 | 1 | 3 | 50,000 | 100,000 |
| 2020-06-01 | 0.4615 | 18 | 39 | 98,653 | 414,581 |
| 2020-03-01 | 1.0 | 22 | 22 | 1,449,867 | 187,347 |
| 2019-12-01 | 0.1071 | 3 | 28 | 106,858 | 601,066 |
| 2019-09-01 | 0.3 | 3 | 10 | 112,650 | 408,545 |
| 2019-06-01 | 0.5 | 4 | 8 | 84,448 | 209,275 |
| 2019-03-01 | 0.6216 | 23 | 37 | 2,024,429 | 1,257,458 |
| 2018-12-01 | 0.3636 | 4 | 11 | 134,596 | 533,644 |
| 2018-09-01 | 0.3333 | 2 | 6 | 45,000 | 254,834 |
| 2018-06-01 | 0.5 | 4 | 8 | 54,000 | 131,600 |
| 2018-03-01 | 1.0 | 10 | 10 | 980,000 | 414,208 |
| 2016-09-01 | 0.6667 | 4 | 6 | 40,000 | 53,800 |
| 2016-06-01 | 2.0 | 2 | 1 | 24,289 | 15,772 |
| 2016-03-01 | 1.7143 | 12 | 7 | 1,205,000 | 115,218 |
| 2015-03-01 | 4.0 | 12 | 3 | 1,200,000 | 115,000 |
| 2014-12-01 | 1.25 | 5 | 4 | 154,500 | 52,500 |
| 2014-09-01 | 0.5556 | 5 | 9 | 62,000 | 124,000 |
| 2014-06-01 | 0.6667 | 2 | 3 | 22,000 | 44,000 |
| 2014-03-01 | 1.6 | 16 | 10 | 786,000 | 175,148 |
| 2013-12-01 | 3.0 | 3 | 1 | 3,500 | 28,000 |
| 2013-09-01 | 3.5 | 7 | 2 | 157,991 | 40,000 |
| 2013-06-01 | 6.0 | 6 | 1 | 475,000 | 105,000 |
| 2013-03-01 | 0.6667 | 4 | 6 | 65,000 | 110,000 |
| 2012-09-01 | 0.6 | 3 | 5 | 100,000 | 75,000 |
| 2012-03-01 | 0.4286 | 3 | 7 | 363,000 | 227,000 |
| 2010-09-01 | 2.5 | 5 | 2 | 655,000 | 200,000 |
| 2010-03-01 | 5.0 | 5 | 1 | 1,003,250 | 10,000 |
| 2008-09-01 | 2.0 | 2 | 1 | 328,000 | 54,688 |
| 2008-06-01 | 2.0 | 4 | 2 | 175,000 | 2,100,000 |
| 2007-03-01 | 0.2727 | 6 | 22 | 437,000 | 1,451,572 |
| 2005-12-01 | 0.5 | 1 | 2 | 750,000 | 25,000 |
| 2005-06-01 | 1.75 | 14 | 8 | 2,925,063 | 1,459,242 |
| 2005-03-01 | 0.3333 | 1 | 3 | 25,000 | 60,000 |
| 2004-12-01 | 0.8 | 4 | 5 | 40,000 | 136,000 |
| 2004-03-01 | 0.2727 | 3 | 11 | 350,000 | 1,344,487 |
Arrowhead Pharmaceuticals Notable Stakeholders
An Arrowhead Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Arrowhead Pharmaceuticals often face trade-offs trying to please all of them. Arrowhead Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Arrowhead Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Christopher Anzalone | CEO and President Director, CEO of Calando, CEO of Tego, CEO of Nantope, CEO of Leonardo and CEO of Ablaris Therapeutics | Profile | |
| Douglas Given | Chairman of the Board | Profile | |
| Edward Frykman | Director, Chairman of Audit Committee, Member of Nomination Committee, Member of Compensation Committee, Director of Insert Therapeutics Inc, Director of Unidym, Director of Aonex and Director of Calando | Profile | |
| Zhen Li | Senior Vice President - Chemistry & Manufacturing | Profile | |
| Susan Boynton | Vice President - Regulatory Affairs | Profile | |
| Peter Leone | Vice President-Strategy & Program Management | Profile | |
| Bruce Given | COO | Profile | |
| Charles McKenney | Independent Director | Profile | |
| Michael Perry | Independent Director | Profile | |
| William Waddill | Independent Director | Profile | |
| Douglass Given | Director | Profile | |
| Mauro Ferrari | Scientific Advisor, Director, Member of Nomination Committee and Member of Compensation Committee | Profile | |
| Nadia MBA | VP Treasurer | Profile | |
| Javier MD | Chief Officer | Profile | |
| Vince Anzalone | IR Contact Officer | Profile | |
| MBA MD | Chief Medicine | Profile | |
| Chad Rubin | IR Contact Officer | Profile | |
| Tracie Oliver | Chief Officer | Profile | |
| PharmD JD | COO Counsel | Profile | |
| Patrick OBrien | General Counsel | Profile | |
| Howard Lovy | Director Communications | Profile | |
| Kenneth Myszkowski | Chief Officer | Profile | |
| Bruce MD | Chief Scientist | Profile | |
| Vincent CFA | Head VP | Profile | |
| Aaron Tan | Head Tax | Profile | |
| Mark Davis | Founder Calando | Profile | |
| David Lewis | Chief Scientific Officer | Profile | |
| Mark Seefeld | Head VP | Profile |
About Arrowhead Pharmaceuticals Management Performance
The success or failure of an entity such as Arrowhead Pharmaceuticals often depends on how effective the management is. Arrowhead Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Arrowhead management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Arrowhead management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.26) | |
| Return On Capital Employed | (0.31) | (0.32) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.87) | (0.91) |
The data published in Arrowhead Pharmaceuticals' official financial statements usually reflect Arrowhead Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Arrowhead Pharmaceuticals. For example, before you start analyzing numbers published by Arrowhead accountants, it's critical to develop an understanding of what Arrowhead Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Arrowhead Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Arrowhead Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Arrowhead Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arrowhead Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Arrowhead Pharmaceuticals' management manipulating its earnings.
Arrowhead Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Arrowhead Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Arrowhead Pharmaceuticals within its industry.Arrowhead Pharmaceuticals Manpower Efficiency
Return on Arrowhead Pharmaceuticals Manpower
| Revenue Per Employee | 458.5K | |
| Revenue Per Executive | 8.6M | |
| Net Loss Per Employee | 398.6K | |
| Net Loss Per Executive | 7.5M | |
| Working Capital Per Employee | 209.6K | |
| Working Capital Per Executive | 3.9M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Arrowhead Stock analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Arrowhead Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrowhead Pharmaceuticals. If investors know Arrowhead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrowhead Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.098 | Earnings Share (2.77) | Revenue Per Share 1.697 | Quarterly Revenue Growth (0.94) | Return On Assets (0.25) |
The market value of Arrowhead Pharmaceuticals is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharmaceuticals' market value can be influenced by many factors that don't directly affect Arrowhead Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arrowhead Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arrowhead Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.